CALL US:022-6101 1700   sales@saffronmedia.in
HOME NEWS INGREDIENT MART EVENTS TOPICS INTERVIEW EDIT
 
News
 
Gireesh Babu, New Delhi October 09 , 2024
The drug regulatory authority may tighten the provisions against those who submit misleading or fake documents to the licensing authority as part of their application for regulatory approvals through an amendment of the existing Drug Rules.

At present, there is no provision under the Drugs Rules, 1945 to address the issue of applicants submitting forged or fabricated, misleading data or documents, etc., for obtaining the regulatory approvals.

The Drugs Technical Advisory Board (DTAB), the body that advises the Central and state governments on technical matters related to drugs in the country, has lately considered this situation and deliberated a proposal to make provisions in the Drugs Rules for taking action against such applicants.

DTAB, following its latest meeting held on August 14, 2024, said that it has deliberated the matter and "recommended that in such cases, the applicant may be debarred for submitting forged/fabricated, misleading data/document, etc. to licensing authority in addition to suspension/cancellation of the product as applicable."

While the Board was informed that there is no provision under the Rules to address the issue, according to information available, the drug regulatory authority has been following the method of rejecting the application and debarring the applicant from applying to any of its offices for any purpose for a period of five years.

An order from the fixed dose combination (FDC) division of the Drug Controller General (India) (DCGI) office in the year 2015, shows that it has declared such a decision after issuing a show cause notice.

"In view of facts and circumstances, it is ample clear that you have submitted forged and fabricated data in connivance with your consultant and QA manager. Therefore, your all applications pending in the FDC division are hereby rejected and you are also debarred for applying to any of the offices of CDSCO (Central Drugs Standard Control Organisation) for any purpose for a period of 5 years," said the order.

It may be noted that there were several instances where an applicant company was alleged to be submitting forged or fake documents with the drug regulatory authority. According to reports, the drug regulator has also questioned some of the multinationals in 2014, in connection with filing documents which are "fraudulent" in nature.

The Union health ministry, in 2015, also initiated efforts to tighten the provisions under the Schedule Y of Drugs Rules, 1945, as a measure to confirm the authenticity of the data or documents submitted by the applicant.

Pharmabiz has reported during the time that the Note under Schedule Y provides that only authentic data should be submitted for the application for permission to import and/or manufacture new drugs for sale or to undertake clinical trials. The data is required to be self certified. It also provides that the licensing authority reserves the right to reject any data or any document(s) if such data or content of such document are found to be of doubtful integrity.

However, the above provision does not explicitly provide for the administrative action which could be taken in case any data on documents submitted is found to be of doubtful integrity. This was discussed in the DTAB during the time and the Board has agreed to the proposed amendment.

Share This Story

Leave a Reply
Your name (required)   Your email (required)
         
Website (required)
   
CommenT
 
Enter Code (Required)

 

 

 
INGREDIENT MART

RECENT NEWS

TOPICS
That foods might provide therapeutic benefits is clearly not a new concept. ...

 

MAIN LINKS OUR SERVICES OTHER PRODUCTS ONLINE MEDIA  
 
About Us
Contact Us
News Archives
 

Product Finder
Features and Articles
News
 
Chronicle Pharmabiz
Food & Bevergae News
Ingredients South Asia
 
Media Information
Rate Card
Advertise
 
 
Copyright © 2023 Saffron Media Pvt Ltd. All Rights Reserved.
Best View in Chrome (103.0) or Firefox (90.0)